Acasă › Cancer ovarian › Alabama
Studii clinice pentru Cancer ovarian în Alabama
27 studii pentru Cancer ovarian caută participanți în Alabama.
Orașe în Alabama
Text oficial al studiului (în engleză)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
În curs de recrutareFaza 2
Toate vârstele · Toate sexele · Actualizat 2 oct. 2026 · NCT05564377A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT06760819177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 1 oct. 2026 · NCT07189871A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0170-USA Mitchell Cancer Institute, Mobile
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Femei · Actualizat 29 sept. 2026 · NCT05128825A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793, Birmingham
- Usa Mitchell Cancer Institute /ID# 276022, Mobile
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Femei · Actualizat 29 sept. 2026 · NCT06890338DESTINY-PANTUMOUR04
- Research Site, Birmingham
În curs de recrutareStudiu observațional
Vârste de la 18 la 130 · Toate sexele · Actualizat 25 sept. 2026 · NCT07124000Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- University of Alabama_6th Ave, Birmingham
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Femei · Actualizat 25 sept. 2026 · NCT03564340A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Alabama at Birmingham, Birmingham
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07213804A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- University of Alabama - Birmingham ( Site 0058), Birmingham
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Femei · Actualizat 17 sept. 2026 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Usa Health Mitchell Cancer Institute, Mobile
În curs de recrutareFaza 2
Vârste de la 18 la 99 · Femei · Actualizat 15 sept. 2026 · NCT07023627FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- The University of Alabama, Birmingham
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 14 sept. 2026 · NCT06303505Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- The University of Alabama at Birmingham, Birmingham
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Femei · Actualizat 14 sept. 2026 · NCT06787612ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Alabama at Birmingham, Birmingham
În curs de recrutareStudiu observațional
Vârste de 18 ani și peste · Toate sexele · Actualizat 14 sept. 2026 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 10 sept. 2026 · NCT06293898A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- University of Alabama at Birmingham ( Site 0006), Birmingham
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Femei · Actualizat 3 sept. 2026 · NCT06824467Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- The University of South Alabama, Mitchell Cancer Institute, Mobile
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Femei · Actualizat 26 aug. 2026 · NCT05281471Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
În curs de recrutareFaza 1/2
12 Months – 30 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT04851119Study of NTB-928 in R/R OC
- The University of Alabama, Birmingham
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Femei · Actualizat 20 aug. 2026 · NCT07690189A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
În curs de recrutare
Vârste de la 35 la 50 · Femei · Actualizat 7 aug. 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 7 aug. 2026 · NCT06580314A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 30 iul. 2026 · NCT04657068The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
- University of Alabama at Birmingham, Birmingham
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
Vârste de la 18 la 99 · Femei · Actualizat 29 iul. 2026 · NCT03538665Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 004, Birmingham
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Femei · Actualizat 16 iul. 2026 · NCT06906341Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Alabama at Birmingham Womens & Infants Center, Birmingham
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Femei · Actualizat 14 iul. 2026 · NCT04606914Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Femei · Actualizat 29 iun. 2026 · NCT05952453Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
În curs de recrutare
Vârste de 18 ani și peste · Toate sexele · Actualizat 30 apr. 2026 · NCT05297734SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
În curs de recrutareStudiu observațional
Toate vârstele · Toate sexele · Actualizat 28 oct. 2025 · NCT03452774Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.